Doctor of Osteopathy Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Paul Malczak

Neurology Prescott, AZ Doctor of Osteopathy

NPI 1003274655 CMS profile 4224501

1001 Willow Creek Rd Ste 3300, Prescott, AZ 86301

Open in the dashboard

General payments

$4,795

285 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Malczak of Prescott, AZ is reported in the CMS Open Payments database as having received $4,795 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $648 41
2024 General $456 31
2023 General $1,668 95
2022 General $1,447 87
2021 General $524 28
2020 General $52 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Malczak
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Paul Malczak were reported at $648. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Paul Malczak Neurology median Middle half National median
2019 $0 $474 $118–$2,177 $163
2020 $52 $367 $82–$2,309 $114
2021 $524 $438 $104–$2,547 $132
2022 $1,447 $442 $103–$2,388 $149
2023 $1,668 $464 $119–$2,312 $160
2024 $456 $468 $119–$2,323 $164
2025 $648 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,257 85 payments
  2. UCB, Inc. $493 40 payments
  3. Biogen, Inc. $325 19 payments
  4. Medtronic, Inc. $255 11 payments
  5. ACADIA Pharmaceuticals Inc $228 13 payments
  6. Alexion Pharmaceuticals, Inc. $216 11 payments
  7. Teva Pharmaceuticals USA, Inc. $205 10 payments
  8. SK Life Science, Inc. $175 7 payments
  9. Genzyme Corporation $160 8 payments
  10. Genentech USA, Inc. $142 7 payments
  11. Other $1,338 74 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,775 284 payments
  2. Education $20 1 payment
Products named General payments · program years 2020–2025
  1. QULIPTA $500 30 payments
  2. Briviact $493 40 payments
  3. UBRELVY $412 28 payments
  4. BOTOX $366 27 payments
  5. SenSight $255 11 payments
  6. NUPLAZID $210 12 payments
  7. AJOVY $205 10 payments
  8. VUMERITY $170 8 payments
  9. AUBAGIO $160 8 payments
  10. ULTOMIRIS $160 8 payments
  11. Other $2,106 123 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 44 drugs

Part D claims

2,452

Median for Neurology: 833

Drug cost

$370,975

Median for Neurology: $202,670

Branded share of claims

30.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuplazid Pimavanserin Tartrate Brand 29 $153,915
Nurtec Odt Rimegepant Sulfate Brand 19 $30,891
Aimovig Autoinjector Erenumab-Aooe Brand 21 $28,882
Ubrelvy Ubrogepant Brand 16 $18,973
Emgality Syringe Galcanezumab-Gnlm Brand 15 $16,420
Xcopri Cenobamate Brand 11 $13,053
Vimpat Lacosamide Brand 12 $12,613
Lacosamide Generic 69 $11,357
Carbidopa-Levodopa Carbidopa/Levodopa Brand 326 $10,335
Frovatriptan Succinate Generic 11 $9,109

The 10 drugs with the highest cost, of 44 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$232,383

Of which drugs: $92,450

Medicare patients

752

Average age 76

Services billed

20,546

417 women, 335 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 54%
Ischemic heart disease 36%
Chronic kidney disease 29%
Depression 29%
Diabetes 28%
Osteoporosis 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 31 19,000 $92,450

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $65
$65 — —
BOTOX
  • AbbVie, Inc. $52
$52 — 19,000
AJOVY
  • Teva Pharmaceuticals USA, Inc. $35
$35 — —
UBRELVY
  • AbbVie, Inc. $32
$32 16 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $31
$31 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record